Therapeutic effect of a new liposome-prednisolone on the puromycin aminonucleoside nephropathy in rats
- Received Date: 2003-12-29
-
Key words:
- prednisolone /
- liposome-prednisolone (lipo-PRED) /
- puromecin aminoneucleoside (PAN) /
- proteinuria
Abstract: Objective To observe the effect of a novel liposome-prednisolone on puromycin aminonucleoside (PAN) nephropathy model in rats. Methods 160~180g BW male Wistar rats were used in this experiment. The rats were given a single injection of PAN at the dose of 4mg/100g BW through right jugular vein to establish the nephrotic syndrome (NS) model. The free prednisolone (PRED) treated group were given (i.p.) the free prednisolone at the dose of 2.0mg/100g BW and the liposome prednisolone (Lipo-PRED) treated group were given (i.v.) the liposome prednisolone at the dose of 1.5mg/100g BW. Urinary protein excretion examined with the biuret method and the monocyte/macrophage, CD4+ T cells and CD8+T cells were analyzed by immunohistochemistry. Results The proteinuria of the Lipo-PRED treated group reduced; the infiltration of monocyte/macrophages, CD4+T cells and CD8+T cells in the glomeruli and interstitium also remarkably weakened. Conclusion The liposome prednisolone can remarkably reduce the proteinuria excretion and leukocyte infiltration both in the glomeruli and tubulointerstitium in the PAN model.
Citation: | LIU Li-hua, OU Zhou-luo, Zhu, Chun-fang. Therapeutic effect of a new liposome-prednisolone on the puromycin aminonucleoside nephropathy in rats[J]. Journal of Pharmaceutical Practice and Service, 2004, (3): 138-140. |